FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.86% | -24.04% | 6.20% | -60.25% | -519.80% |
| Total Depreciation and Amortization | 1.30% | 12.14% | 27.95% | 5.23% | 6.99% |
| Total Amortization of Deferred Charges | -- | -100.00% | -- | -- | -- |
| Total Other Non-Cash Items | -22.02% | 371.12% | -70.32% | 613.82% | 106.89% |
| Change in Net Operating Assets | -2,403.45% | 112.11% | 69.20% | -457.35% | -534.09% |
| Cash from Operations | 20.37% | 0.30% | 24.47% | -71.66% | -17.92% |
| Capital Expenditure | 100.00% | 97.18% | -395.35% | 56.57% | -800.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 97.18% | -395.35% | 56.57% | -800.00% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 33.14% |
| Issuance of Common Stock | -- | -- | -- | -- | -99.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -- | -- | 108.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.68% | -2,334.83% | 103.35% | -186.36% | 232.15% |